Association between expression of nuclear receptor co‑activator 5 protein and prognosis in postoperative patients with osteosarcoma

Wu,Ya; Wu,Jian; Dong,Qi‑Rong; Guo,Nai‑Zhou

doi:10.3892/ol.2017.7513

Association between expression of nuclear receptor co‑activator 5 protein and prognosis in postoperative patients with osteosarcoma

Authors:
- Ya Wu
- Jian Wu
- Qi‑Rong Dong
- Nai‑Zhou Guo
View Affiliations

Affiliations: Department of Orthopedics, Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu 215004, P.R. China, Department of Laboratory Medicine, The First People's Hospital of Yancheng City, Yancheng, Jiangsu 224005, P.R. China
Published online on: December 5, 2017 https://doi.org/10.3892/ol.2017.7513
Pages: 1888-1892

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between the expression of nuclear receptor co‑activator 5 protein (NCOA5) and the prognosis of postoperative patients with osteosarcoma. Human osteosarcoma samples were collected from 145 patients and normal bone tissues were collected from 100 individuals as controls. Immunohistochemistry (IHC) and reverse transcription‑polymerase chain reaction (RT‑PCR) were employed to measure the levels of NCOA5 protein in cases of human osteosarcoma. The results from the RT‑PCR analysis demonstrated that the positive rate of NCOA5 mRNA expression in human osteosarcoma was 17.24% (25/145). The positive rate in normal bone tissues was 84.00% (84/100), which was significantly higher compared with that of human osteosarcoma tissues (χ2=33.166; P<0.001). IHC staining indicated that the positive rate of NCOA5 protein in the osteosarcoma samples was 26.21% (38/145). The positive rate in normal bone tissues was 82.00% (82/100), which was significantly increased compared with that of human osteosarcoma tissues (χ2=28.166; P<0.001). NCOA5 mRNA and protein expression levels were consistent in human osteosarcoma tissues, and were lower than in control tissues. The expression of NCOA5 was low in human osteosarcoma tissues, while it was high in normal bone tissues. These low NCOA5 expression levels were associated with postoperative survival of human osteosarcoma.

View Figures

View References

1	Huang J, Liu K, Song D, Ding M, Wang J, Jin Q and Ni J: Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer Sci. 107:242–249. 2016. View Article : Google Scholar : PubMed/NCBI
2	Li YS, Deng ZH, Zeng C and Lei GH: JNK pathway in osteosarcoma: Pathogenesis and therapeutics. J Recept Signal Transduct Res. 36:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, et al: The current and future therapies for human osteosarcoma. Curr Cancer Ther Rev. 9:55–77. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chakravarthi PS, Kattimani VS, Prasad LK and Satish PR: Juxtacortical osteosarcoma of the mandible: Challenges in diagnosis and management. Natl J Maxillofac Surg. 6:127–131. 2015. View Article : Google Scholar : PubMed/NCBI
5	Commandeur AE, Styer AK and Teixeira JM: Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update. 21:593–615. 2015. View Article : Google Scholar : PubMed/NCBI
6	Zhou W, Zhu Y, Chen S, Xu R and Wang K: Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma. Mol Med Rep. 13:713–719. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yang J, Cheng D, Zhou S, Zhu B, Hu T and Yang Q: Overexpression of X-box binding protein 1 (XBP1 correlates to poor prognosis and up-regulation of PI3K/mTOR in human osteosarcoma. Int J Mol Sci. 16:28635–28646. 2015. View Article : Google Scholar : PubMed/NCBI
8	Liu CY and Feng GS: NCOA5, a molecular link between type 2 diabetes and liver cancer. Hepatobiliary Surg Nutr. 3:106–108. 2014.PubMed/NCBI
9	Tetel MJ, Auger AP and Charlier TD: Who's in charge? Nuclear receptor coactivator and corepressor function in brain and behavior. Front Neuroendocrinol. 30:328–342. 2009. View Article : Google Scholar : PubMed/NCBI
10	Gao S, Li A, Liu F, Chen F, Williams M, Zhang C, Kelley Z, Wu CL, Luo R and Xiao H: NCOA5 Haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell. 24:725–737. 2013. View Article : Google Scholar : PubMed/NCBI
11	Lahusen T, Henke RT, Kagan BL, Wellstein A and Riegel AT: The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat. 116:225–237. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chauhan C, Zraly CB, Parilla M, Diaz MO and Dingwall AK: Histone recognition and nuclear receptor co-activator functions of Drosophila cara mitad, a homolog of the N-terminal portion of mammalian MLL2 and MLL3. Development. 139:1997–2008. 2012. View Article : Google Scholar : PubMed/NCBI
13	Chen VW, Ruiz BA, Hsieh MC, Wu XC, Ries LA and Lewis DR: Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 120 Suppl 23:S3781–S3792. 2014. View Article : Google Scholar
14	Chinenov Y, Gupte R and Rogatsky I: Nuclear receptors in inflammation control: Repression by GR and beyond. Mol Cell Endocrinol. 380:55–64. 2013. View Article : Google Scholar : PubMed/NCBI
15	Pavlin MR, Brunzelle JS and Fernandez EJ: Agonist ligands mediate the transcriptional response of nuclear receptor heterodimers through distinct stoichiometric assemblies with coactivators. J Biol Chem. 289:24771–24778. 2014. View Article : Google Scholar : PubMed/NCBI
16	Gyamfi MA and Wan YJ: Pathogenesis of alcoholic liver disease: The role of nuclear receptors. Exp Biol Med (Maywood). 235:547–560. 2010. View Article : Google Scholar : PubMed/NCBI
17	Brand TM, Iida M, Li C and Wheeler DL: The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med. 12:419–432. 2011.PubMed/NCBI
18	Poos K, Smida J, Maugg D, Eckstein G, Baumhoer D, Nathrath M and Korsching E: Genomic heterogeneity of osteosarcoma-shift from single candidates to functional modules. PLoS One. 10:e01230822015. View Article : Google Scholar : PubMed/NCBI
19	Basu-Roy U, Basilico C and Mansukhani A: Perspectives on cancer stem cells in osteosarcoma. Cancer Lett. 338:158–167. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zhao R, Ni D, Tian Y, Ni B and Wang A: Aberrant ADAM10 expression correlates with osteosarcoma progression. Eur J Med Res. 19:92014. View Article : Google Scholar : PubMed/NCBI
21	Talmadge JE and Gabrilovich DI: History of myeloid-derived suppressor cells. Nat Rev Cancer. 13:739–752. 2013. View Article : Google Scholar : PubMed/NCBI
22	Dhar D, Seki E and Karin M: NCOA5, IL-6, Type-2 diabetes and HCC: The deadly quartet. Cell Metab. 19:6–7. 2014. View Article : Google Scholar : PubMed/NCBI
23	Cumsille P, Coronel A, Conca C, Quiñinao C and Escudero C: Proposal of a hybrid approach for tumor progression and tumor-induced angiogenesis. Theor Biol Med Model. 12:132015. View Article : Google Scholar : PubMed/NCBI
24	Arvelo F, Sojo F and Cotte C: Tumour progression and metastasis. Ecancermedicalscience. 10:6172016. View Article : Google Scholar : PubMed/NCBI
25	Gillespie MA, Gold ES, Ramsey SA, Podolsky I, Aderem A and Ranish JA: An LXR-NCOA5 gene regulatory complex directs inflammatory crosstalk-dependent repression of macrophage cholesterol efflux. EMBO J. 34:1244–1258. 2015. View Article : Google Scholar : PubMed/NCBI
26	Lee E, Pandey NB and Popel AS: Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment. Expert Rev Mol Med. 17:e32015. View Article : Google Scholar : PubMed/NCBI
27	Marcu LG and Harriss-Phillips WM: In Silico modelling of treatment-induced tumour cell kill: Developments and advances. Comput Math Methods Med. 2012:9602562012. View Article : Google Scholar : PubMed/NCBI
28	Fang M, Yuan J, Peng C and Li Y: Collagen as a double-edged sword in tumor progression. Tumour Biol. 35:2871–2882. 2014. View Article : Google Scholar : PubMed/NCBI
29	Lin G, Sun XJ, Han QB, Wang Z, Xu YP, Gu JL, Wu W, Zhang GU, Hu JL, Sun WY and Mao WM: Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncol Lett. 10:901–906. 2015. View Article : Google Scholar : PubMed/NCBI
30	Shiomi H, Eguchi Y, Tani T, Kodama M and Hattori T: Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol. 156:567–575. 2000. View Article : Google Scholar : PubMed/NCBI